About: CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the study were to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the study were to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). (en)
Title	CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT (en)
skos:prefLabel	CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT (en)
skos:notation	RIV/00216224:14110/05:00019164!RIV10-MZ0-14110___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NR8445)
http://linked.open...iv/cisloPeriodika	11
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Kuhrová, Viera Pospíšilová, Šárka Dvořáková, Dana Brychtová, Yvona Kuglík, Petr Mentzlová, Dita Doubek, Michael Mayer, Jiří Šmardová, Jana Malčíková, Jitka Svitáková, Miluše Trbušek, Martin Skuhrová Francová, Hana Čejková, Soňa
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	515031
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/05:00019164
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	B-CLL IgVH p53 previos treatment (en)
http://linked.open.../riv/klicoveSlovo	B-CLL IgVH p53 previos treatment
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[AF338F1869E2]
http://linked.open...i/riv/nazevZdroje	Blood
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	14 (xsd:int)
http://linked.open...cetTvurcuVysledku	16 (xsd:int)
http://linked.open...vavai/riv/projekt	In vitro sensitivity/resistance of CLL cells with inactivated p53 on modern therapy
http://linked.open...UplatneniVysledku	2005
http://linked.open...v/svazekPeriodika	2005
http://linked.open...iv/tvurceVysledku	Brychtová, Yvona Doubek, Michael Dvořáková, Dana Kuglík, Petr Mayer, Jiří Pospíšilová, Šárka Malčíková, Jitka Svitáková, Miluše Trbušek, Martin Šmardová, Jana Francová, Hana Mentzlová, Dita Čejková, Soňa Kuhrová, Viera Kujíčková, Jitka Linková, Věra
http://linked.open...ain/vavai/riv/wos	00023342600
issn	0006-4971
number of pages	2 (xsd:int)
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software